Lonsurf ([trifluridine + tipiracil]; Otsuka/Servier) Drug Analysis 2016-2025 - ResearchAndMarkets.com

The "Drug analysis: Lonsurf" drug pipelines has been added to ResearchAndMarkets.com's offering.

Lonsurf ([trifluridine + tipiracil]; Otsuka/Servier) is an oral combination drug with both anti-angiogenic and cytotoxic effects.

It is composed of trifluridine, an antineoplastic nucleoside analog, and tipiracil hydrochloride, a thymidine phosphorylase inhibitor. Following uptake into the cancer cells, trifluridine is incorporated into DNA, thereby interfering with DNA synthesis and inhibiting cell proliferation.

Tipiracil hydrochloride increases the bioavailability of trifluridine by preventing its rapid metabolism and ensuring the blood concentration of trifluridine is maintained.

Key Topics Covered:

List of Figures

Figure 1: Lonsurf for colorectal cancer - SWOT analysis

Figure 2: Drug assessment summary of Lonsurf for colorectal cancer

Figure 3: Drug assessment summary of Lonsurf for colorectal cancer

Figure 4: Lonsurf sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016-25

List of Tables

Table 1: Lonsurf drug profile

Table 2: Lonsurf Phase III data in colorectal cancer

Table 3: Lonsurf Phase II trials in colorectal cancer

Table 4: Lonsurf sales for colorectal cancer across the US, Japan, and five major EU markets, by country M, 2016-25

Table 5: Patients treated with Lonsurf across the US, Japan, and five major EU markets, by country, 2016-25

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/dbtstc/lonsurf?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180215006240/en/